The human supraoptic nucleus (SON) is the main production site of plasma arginine-vasopressin (AVP). The present study aimed to define the subpopulation of patients in which multinucleated SON neurons (MNN) are present. We determined the proportion of MNN in immunocytochemically defined SON AVP population and compared AVP mRNA levels in the SON of 29 patients with and without MNN. Interestingly, MNN appeared to be present in a high proportion in patients with pneumonia and other pulmonary pathologies (Pul P). The percentage of MNN in the SON of Pul P patients turned out to be age- and sex-dependent. In young women with Pul P their proportion was 10 times higher than in women without such a pathology and in young men with Pul P their frequency was 22 times higher than in other men. In those patients with the highest proportion of MNN, i.e. young females and males with Pul P, AVP mRNA expression in the SON was the lowest. In addition, young women (≤50 years old) had lower AVP mRNA levels than young men and than elderly women (>50 years old). In conclusion, our study suggests that multinucleated neurons are a hallmark of Pul P in the human SON and that this phenomenon may be accompanied by lower AVP production in young subjects.

Keywords:
Vasopressin, Sex dimorphism, Supraoptic nucleus, Ageing, Multinucleated neurons, Vacuolized neurons, Pulmonary pathology, Clinical neuroendocrinology
1.
Swaab DF: Neurobiology and neuropathology of the human hypothalamus; in Bjorklund A, Hokfelt T, et al. (eds): Handbook of Chemical Neuroanatomy. Amsterdam, Elsevier, 1997, pp 39–137.
2.
Swaab DF: The human hypothalamo-neurohypophyseal system in health and disease. Prog Brain Res 1998;119:577–618.
3.
Ishunina TA, Salehi A, Hofman MA, Swaab DF: Activity of vasopressinergic neurones of the human supraoptic nucleus is age- and sex-dependent. J Neuroendocrinol 1999;11:251–258.
4.
Ishunina TA, Swaab DF: Vasopressin and oxytocin neurons of the human supraoptic and paraventricular nucleus: Size changes in relation to age and sex. J Clin Endocrinol Metab 1999;84:4637–4644.
5.
Scharrer E, Gaupp R: Neure Befunde am Nucleus supraopticus and Nucleus paraventricularis des Menschen. Z Ges Neurol Psychiat 1933;148:766–772.
6.
Scharrer E, Scharrer B: The hypothalamus and central levels of autonomic function. Fitel 1940;202:170–194.
7.
Prelevic GM, Jacobs HS: Menopause and post-menopause. Baillière’s Clin Endocrinol Metab 1997;11:311–340.
8.
Friedman AS, Malott KA, Memoli VA, Pais SI, Yu XM, North WG: Products of vasopressin gene expression in small cell carcinoma of the lung. Br J Cancer 1994;69:260–263.
9.
Evans DAP, Burbach JPH, Swaab DF, Van Leeuwen FW: Mutant vasopressin precursors in the human hypothalamus: Evidence for neuronal somatic mutations in man. Neuroscience 1996;71:1025–1030.
10.
Lucassen PJ, Goudsmit E, Pool CW, Mengod G, Palacios JM, Raadsheer FC, Guldenaar SEF, Swaab DF: In situ hybridization for vasopressin mRNA in the human supraoptic and paraventricular nucleus: Quantitative aspects of formalin-fixed paraffin-embedded tissue sections as compared to cryostat sections. J Neurosci Methods 1995;57:221–230.
11.
Lucassen PJ, Van Heerikhuize JJ, Guldenaar SEF, Pool CW, Hofman MA, Swaab DF: Unchanged amounts of vasopressin mRNA in the supraoptic and paraventricular nucleus during aging and in Alzheimer’s disease. J Neuroendocrinol 1997;9:297–305.
12.
Mohr E, Hillers M, Ivell R, Haulica ID, Richter D: Expression of the vasopressin and oxytocin genes in human hypothalami. FEBS Lett 1985;193:12–16.
13.
Mengod G, Charli JL, Palacios JM: The use of in situ hybridization histochemistry for the study of neuropeptide gene expression in the human brain. Cell Mol Neurobiol 1990;10:113–126.
14.
Mengod G, Goudsmit E, Probst A, Palacios JM: In situ hybridization histochemistry in the human hypothalamus. Prog Brain Res 1992;93:45–55.
15.
Jongkind JF, Swaab DF: The distribution of thiamine diphosphate-phosphohydrolase in the neurosecretory nuclei of the rat following osmotic stress. Histochemie 1967;11:319–324.
16.
Swaab DF, Jongkind JF: The hypothalamic neurosecretory activity during the oestrous cycle, pregnancy, parturition, lactation, and after gonadectomy, in the rat. Neuroendocrinology 1970;6:133–145.
17.
Lucassen PJ, Salehi A, Pool CW, Gonatas NK, Swaab DF: Activation of vasopressin neurons in aging and Alzheimer’s disease. J Neuroendocrinol 1994;6:673–679.
18.
Salehi A, Lucassen PJ, Pool CW, Gonatas NK, Ravid R, Swaab DF: Decreased neuronal activity in the nucleus basalis of Meynert in Alzheimer’s disease as suggested by the size of the Golgi apparatus. Neuroscience 1994;59:871–880.
19.
Bartter FC, Schwartz WB: The syndrome of inappropriate secretion of antidiuretic hormone. Am J Med 1967;42:790–806.
20.
Rosenow EC, Segar WE, Zehr JE: Inappropriate antidiuretic hormone secretion in pneumonia. Mayo Clin Proc 1972;47:169–174.
21.
Shalhoub RJ, Antoniou LD: The mechanism of hyponatremia in pulmonary tuberculosis. Ann Intern Med 1969;70:943–962.
22.
Segar WE, Moore WW: Hyponatremia: Increased antidiuretic hormone and ‘inappropriate’ thirst in a patient with bronchogenic carcinoma. Minn Med 1968;51:625–629.
23.
White RJ, Woodings DF: Impaired water handling in chronic obstructive airways diseases. BMJ 1971;ii:561–563.
24.
Sladen A, Laver MB, Pontoppidan H: Pulmonary complications and water retention in prolonged mechanical ventilation. N Engl J Med 1968;279:448–453.
25.
Coulson JM, Fiskerstrand CE, Woll PJ, Quinn JP: Arginine vasopressin promoter regulation is mediated by a neuron-restrictive silencer element in small cell lung cancer. Cancer Res 1999;59:5123–5127.
26.
Baker JW, Yerger S, Segar WE: Elevated plasma antidiuretic hormone levels in status asthmaticus. Mayo Clin Proc 1976;51:31–34.
27.
Du Souich P, Saunier C, Hartemann D, Sautegeau A, Ong H, Larose P, Babini R: Effects of moderate hypoxemia on atrial natriuretic factor and arginine vasopressin in normal man. Biochem Biophys Res Commun 1987;148:906–912.
28.
Ashack R, Farber MO, Weinberger MH, Robertson GL, Fineberg NS, Manfredi F: Renal and hormonal responses to acute hypoxia in normal individuals. J Lab Clin Med 1985;106:12–16.
29.
Reihman DH, Farber MO, Weinberger MH, Henry DP, Fineberg NS, Dowdeswell IR, Burt RW, Manfredi F: Effect of hypoxemia on sodium and water excretion in chronic obstructive lung disease. Am J Med 1985;78:87–94.
30.
Rao M, Eid N, Herrod L, Parekh A, Steiner P: Antidiuretic hormone response in children with bronchopulmonary dysplasia during episodes of acute respiratory distress. Am J Dis Child 1986;140:825–828.
31.
Koller EA, Buhrer A, Felder L, Schopen M, Vallotton MB: Altitude diuresis: Endocrine and renal responses to acute hypoxia of acclimatized and non-acclimatized subjects. Eur J Appl Physiol 1991;62:228–234.
32.
Ferlito A, Rinaldo A, Devaney KO: Syndrome of inappropriate antidiuretic hormone secretion associated with head and neck cancers: Review of the literature. Ann Otol Rhinol Laryngol 1997;106:878–883.
33.
Share L, Crofton JT, Ouchi Y: Vasopressin: Sexual dimorphism in secretion, cardiovascular actions and hypertension. Am J Med Sci 1988;295:314–319.
34.
Van Londen L, Goekoop JG, Van Kempen GMJ, Frankhuijzen-Sierevogel AC, Wiegant VM, Van der Velde EA, De Wied D: Plasma levels of arginine vasopressin elevated in patients with major depression. Neuropsychopharmacology 1997;17:284–292.
© 2000 S. Karger AG, Basel
2000
Copyright / Drug Dosage / Disclaimer
Copyright: All rights reserved. No part of this publication may be translated into other languages, reproduced or utilized in any form or by any means, electronic or mechanical, including photocopying, recording, microcopying, or by any information storage and retrieval system, without permission in writing from the publisher.
Drug Dosage: The authors and the publisher have exerted every effort to ensure that drug selection and dosage set forth in this text are in accord with current recommendations and practice at the time of publication. However, in view of ongoing research, changes in government regulations, and the constant flow of information relating to drug therapy and drug reactions, the reader is urged to check the package insert for each drug for any changes in indications and dosage and for added warnings and precautions. This is particularly important when the recommended agent is a new and/or infrequently employed drug.
Disclaimer: The statements, opinions and data contained in this publication are solely those of the individual authors and contributors and not of the publishers and the editor(s). The appearance of advertisements or/and product references in the publication is not a warranty, endorsement, or approval of the products or services advertised or of their effectiveness, quality or safety. The publisher and the editor(s) disclaim responsibility for any injury to persons or property resulting from any ideas, methods, instructions or products referred to in the content or advertisements.
You do not currently have access to this content.